Objective: 3,5,3 0 -Triiodothyronine (T 3 )-predominant Graves' disease is characterized by the increasing volume of thyroid goiter resulting in poor prognosis. Although type 1 and type 2 iodothyronine deiodinases (DIO1 and DIO2 respectively) are known to be overexpressed in the thyroid tissues of T 3 -predominant Graves' disease, the pathogenesis of this disease is still unclear. The aim of our study is to identify genes that characterize T 3 -predominant Graves' disease tissue in order to clarify the molecular mechanism of this disease. Design and methods: mRNAs from two thyroid tissues of both typical T 3 -predominant and common-type Graves' disease were analyzed with DNA microarrays with probes for 28 869 genes. Genes identified to be differentially expressed between the two groups were further analyzed in the second and third screenings using 70 Graves' thyroid tissues by real-time quantitative RT-PCR. Results: Twenty-three candidate genes were selected as being differentially expressed in the first screening with microarrays. Among these, seven genes, leucine-rich repeat neuronal 1 (LRRN1), bone morphogenetic protein 8a (BMP8A), N-cadherin (CDH2), phosphodiesterase 1A (PDE1A), creatine kinase mitochondrial 2 (CKMT2), integrin beta-3 (ITGB3), and protein tyrosine phosphatase nonreceptor type 4 (PTPN4), were confirmed to be differentially expressed in DIO1 or DIO2 over-and underexpressing Graves' tissues. Conclusions: These genes are related to the characteristics of T 3 -predominant Graves' disease, such as high titer level of serum anti-TSH receptor antibody, high free T 3 to free thyroxine ratio, and a large goiter size. They might play a role in the pathogenesis of T 3 -predominant Graves' disease.
Introduction
Treatment with antithyroid drugs usually results in normalization of the serum thyroid hormone levels in Graves' disease, but w12% of patients, with cases called 3, 5, 3 0 -triiodothyronine (T 3 )-predominant Graves' disease, show elevated serum T 3 level after serum thyroxine (T 4 ) becomes normal or even low (1) . Patients with T 3 -predominant Graves' disease have larger thyroid glands and their sizes tend to increase rapidly, resulting in resistance to antithyroid drug treatment (2, 3, 4, 5) . The prevalence of T 3 -predominant Graves' disease is high in younger patients (6) . Thyroid tissues of T 3 -predominant Graves' disease have some typical histological features; for example, the tissue is rich in follicular cells while colloid content is low, and the height of their thyroid follicular epithelial cells is greater than that from patients with the common type of Graves' disease (7) .
The source of the high serum T 3 level had not been clarified for a long time. Recently, we found that increase in type 1 and type 2 iodothyronine deiodinase (D1/DIO1 and D2/DIO2 respectively) activities may be the cause of the higher serum T 3 /T 4 in T 3 -predominant Graves' disease (6) . However, many other questions related to the pathogenesis of this disease, for example, why T 3 -predominant Graves' disease is often observed in young patients or why the thyroid gland shows rapid growth, remain obscure.
In order to clarify the difference between T 3 -predominant and common-type Graves' diseases at the molecular level, we analyzed the gene expression profiles in the thyroid tissues from cases of Graves' disease and identified seven genes that characterize T 3 -predominant Graves' disease.
Materials and methods

Thyroid tissues
Thyroid tissues from 74 patients with Graves' disease were collected immediately after surgery at Kuma Hospital. These patients were confirmed to have Graves' disease by the serum anti-TSH receptor antibody (TRAb) titer level at the first visit. The patients' informed consent was obtained and the study protocol was approved by the Institutional Ethics Committee. A portion of the resected thyroid tissues was frozen in liquid nitrogen for RNA extraction. The rest of the tissues were fixed in 15% buffered formaldehyde (pH 5.8). After fixation, 5 mm sections were prepared from paraffin-embedded blocks, stained with hematoxylin and eosin, and then examined microscopically. Frozen thyroid tissues were homogenized and total RNA was extracted as described previously (8) .
Thyroid function tests
Serum concentrations of TSH, free T 4 (FT 4 ), and free T 3 (FT 3 ) with reference ranges of 0.3-5.0 mIU/ml, 0.7-1.6 ng/dl, and 0.17-0.37 ng/dl respectively were measured with a chemiluminescent immunoassay (ARCHTECT i2000, Abbott Japan). TRAb titer levels were measured using an ECLusys TRAb (Roche Diagnostic Japan) with a reference range of !1.3 IU/l. The volume of the thyroid gland was measured by ultrasonography as reported previously (9) .
RT
Five microliters of each extracted total RNA were reverse transcribed in an RT mixture, which consisted of 10 ml of 5! first-strand buffer (Invitrogen), 10 mmol/l dithiothreitol, 0.5 mmol/l dNTP (Takara, Shiga, Japan), 500 U Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen), 2 U/ml RNase inhibitor (Takara), and 2.5 mmol/l random hexamer (Takara) in a total volume of 50 ml. The RT reaction was performed for 10 min at 25 8C, 50 min at 37 8C, and 15 min at 70 8C.
Real-time quantitative RT-PCR with TaqMan chemistry
The expression levels of DIO1, DIO2, and ACTB mRNA were measured using THUNDERBIRD Probe qPCR Mix (Toyobo Life Science, Osaka, Japan) and ABI PRISM 7900HT (Applied Biosystems) according to the manufacturers' instructions. One microliter of cDNA, 0.5 mM each primer, and 7 mM TaqMan probe were used in an assay. Primers and probes were purchased from Operon Biotechnologies (Tokyo, Japan) and are listed in Table 1 . The conditions of the PCR were as follows: 95 8C for 1 min and 40 cycles of 95 8C for 15 s and 60 8C for 1 min. A recombinant pGEM T-vector (Promega) containing a partial cDNA was constructed by PCR cloning with the same primer sets as used in the PCR and was used as a standard sample. Table 1 Primers and probes used in the first, second, and third screenings.
First screening with DNA microarrays
Among the 74 thyroid tissues collected, two tissues (T1 and T2) were selected as representatives of T 3 -predominant Graves' tissue according to the following criteria using the method described by Takamatsu et al. (7): i) the tissues showed typical morphological features of T 3 -predominant Graves' disease, such as being rich in follicular cells while their colloid content was low (relative area of the epithelium element was more than 20%), with their thyroid follicular epithelial cells being tall (mean height of the epithelium was more than 10 mm); ii) not being accompanied by tumor; iii) being accompanied by no or only slight lymphocyte infiltration; and iv) overexpressing both DIO1 and DIO2 mRNAs. Two tissues (C1 and C2) were selected as representatives of commontype Graves' tissue according to the following criteria: i) the tissues showed typical morphological features of common-type Graves' disease, such as being poor in follicular cells while their colloid content was high (relative area of the epithelium element was !10%), with their thyroid follicular epithelial cells being short (mean height of the epithelium was !7 mm); ii) not being accompanied by tumor; iii) being accompanied by no or only slight lymphocyte infiltration; and iv) underexpressing both DIO1 and DIO2 mRNAs. Among these patients, T1, T2, and C1 were administrated 150 mg potassium iodide, 400 mg propylthiouracil, 100 mg potassium iodide, and 50 mg propylthiouracil respectively at surgery. As for C2, TRAb was negative at surgery; however, she was diagnosed with Graves' disease with elevated TRAb at her first visit and a large goiter due to enlarged follicles was present at surgery. Thus, we regarded her as a case of transient remission of Graves' disease. These tissues were not used in the second and third screenings.
One hundred micrograms of total RNA extracted from each tissue were labeled and analyzed with GeneChip Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's protocol. Twenty eight thousand eight hundred and sixty nine genes were analyzed. Signals were quantified with Expression Console Software (Affymetrix) and subjected to quantile normalization. SDS (Z-scores) of each gene in four comparisons (C1 vs T1, C2 vs T1, C1 vs T2, and C2 vs T2) were calculated. 
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T1 T2 Figure 1 Microscopic images of the tissues analyzed in the first screening with microarray (!100). C1 and C2 were poor in follicular cells while their colloid content was high, and their thyroid follicular epithelial cells were short. T1 and T2 were rich in follicular cells while their colloid content was low, and their thyroid follicular epithelial cells were tall. Slight lymphocytic infiltrations were observed in C2. a A greater Z-score represents a higher gene expression level in the T 3 -predominant Graves' tissues (T1 and T2).
Second screening
In the second screening, four samples overexpressing both DIO1 and DIO2 mRNAs and four samples underexpressing both DIO1 and DIO2 mRNAs were analyzed by quantitative RT-PCR with SYBR Green I chemistry. These samples were not used in the third screening. The expression levels of 23 mRNAs were measured using THUNDERBIRD SYBR qPCR Mix (Toyobo Life Science) and ABI PRISM 7900HT according to the manufacturers' instructions. One microliter of cDNA and 0.5 mM of each primer were used in an assay. Primers were purchased from Operon Biotechnologies and are listed in Table 2 . The conditions of the PCR were as follows: 95 8C for 1 min and 40 cycles of 95 8C for 15 s and 60 8C for 1 min. Ct values in each tissue sample were calculated. Genes for which the expression levels in all four samples overexpressing DIO1 and DIO2 mRNAs were higher or lower than those in all four samples underexpressing DIO1 and DIO2 mRNAs were subjected to the third screening.
Third screening
Quantitative RT-PCR analysis described earlier was performed using RNAs from 62 Graves' tissues. A recombinant pGEM T-vector containing a partial cDNA was constructed by PCR cloning with the same primer sets as used in the PCR and was used as a standard sample.
Statistical analysis
Data were analyzed with StatMate Software (Atoms, Tokyo, Japan). Statistical analysis of differences between the groups was carried out using the Mann-Whitney U test. A P value !0.05 was considered significant.
Results
Data of the patients analyzed in the first screening are shown in Table 3 . Morphologies of each tissue are shown in Fig. 1 . In the first screening, genes showing Z-scores O2 or !K2 in all four comparisons (C1 vs T1, C2 vs T1, C1 vs T2, and C2 vs T2) were selected. After excluding genes with a weak microarray signal, we chose 23 genes listed in Table 4 . These genes were subjected to the second screening by quantitative RT-PCR. Data of the patients analyzed in the second screening are shown in Table 5 . Among the 23 genes, nine genes showed a clear difference in expression between DIO1 and DIO2 over-and underexpressing groups.
The expression levels of these nine genes were measured in 62 Graves' tissues. First, data were analyzed comparing the highest 20 and lowest 20 samples in terms of DIO1 mRNA expression. Data of the patients analyzed and gene expressions are summarized in Table 6 and Fig. 2 . Significant differences were observed in terms of FT 3 to FT 4 ratio, TRAb, and thyroid volume. Seven genes, leucine-rich repeat neuronal 1 (LRRN1), bone morphogenetic protein 8a (BMP8A), N-cadherin (CDH2), phosphodiesterase 1A (PDE1A), creatine kinase mitochondrial 2 (CKMT2), integrin beta-3 (ITGB3), and protein tyrosine phosphatase non-receptor type 4 (PTPN4), were confirmed to show a significant difference in their expression level between DIO over-and underexpressing groups. Secondly, data were analyzed comparing the highest 20 and lowest 20 samples in terms of DIO2 mRNA expression. Data of the patients analyzed and gene expressions are summarized in Table 7 and Fig. 3 . Significant differences were observed in terms of FT 3 to FT 4 ratio, TRAb, and thyroid volume. The same set of seven genes that were detected in DIO1 analysis, LRRN1, BMP8A, CDH2, PDE1A, CKMT2, ITGB3, and PTPN4, were confirmed to show a significant difference in their expression level between DIO2 over-and underexpressing groups. One gene, C17orf57 (Efcab13), showed a significant difference; however, its expression increased in DIO1-and DIO2-overexpressing samples in the first and second screenings, whereas it decreased in the third screening. This phenomenon was probably caused by three samples in the third screening having low DIO2 expression and extremely high C17orf57 expression. In summary, in Graves' tissues overexpressing DIO1 or DIO2, seven genes, LRRN1, BMP8A, CDH2, PDE1A, CKMT2, ITGB3, and PTPN4, were also overexpressed. Among these genes, CDH2 was the most differentially expressed and its expression level in DIO1-and DIO2-overexpressing tissues was approximately ten times greater than that in DIO1-and DIO2-underexpressing tissues. Medication in the patients in these four groups at surgery is summarized in Table 8 . In all groups, the majority of the patients administrated methimazole and/or potassium iodide. Next, data were analyzed comparing the highest 20 and lowest 20 samples in terms of TRAb, FT 3 to FT 4 ratio, and goiter size (Tables 9, 10, and 11). All these seven genes showed a significant increase in expression level in the high TRAb and FT 3 to FT 4 ratio groups and in the large goiter group.
Discussion
In this study, we identified seven genes that were overexpressed in Graves' tissues with high DIO1 or DIO2 expression. The most important start point of our study was how to distinguish T 3 -predominant Graves' disease from common-type Graves' disease, as the definitive criteria to distinguish T 3 -predominant Graves' disease have not been established yet. The main characteristics of T 3 -predominant Graves' disease are as follows: patients are young, goiter is large, serum T 3 level is elevated compared with T 4 , and TRAb is high. Thyroid tissue of T 3 -predominant Graves' disease shows typical morphology and elevated D1 and D2 expression. However, after collecting tissue samples, we found that cases of T 3 -predominant Graves' disease that show all these characteristics were quite rare. Thus, we had to decide which factors should be given priority.
As for the morphology, the majority of the tissues have a mixture of T 3 -predominant and common-type morphology. Another problem when we tried to use morphology as a criterion was the fact that objective evaluation was quite difficult. Even though Takamatsu et al. (7) established a morphological criterion of T 3 -predominant Graves' disease, objective differentiation was quite complicated, and as there are at least two features that characterize T 3 -predominant Graves' disease, we had to establish some scoring system for objective differentiation. For the above reasons, we decided not to use morphology to separate T 3 -predominant Graves' from the common-type in the second and third screenings in which we had to deal with many cases.
FT 3 to FT 4 ratio was another candidate criterion. However, we found that FT 3 to FT 4 ratio varied during the clinical course, especially after the use of antithyroidal drugs. In Japan, most patients choose drug therapy. Usually, only patients who have some troubles with antithyroidal drugs, for example, they show poor hormone control or side effects, or their goiter is too large, undergo surgery. As a result, patients who undergo an operation tend to be administered various drugs at various doses and periods before the operation, as serum T 3 level should be kept within the normal range at surgery. Thus, it is hard to estimate the effects of such drugs on the FT 3 to FT 4 ratio in each patient.
Considering these facts, we decided to use four factors, morphology, FT 3 to FT 4 ratio, and DIO1 and DIO2 mRNA expression to pick up a small number of typical tissues for the first screening. We then used DIO1 and DIO2 mRNA expression in the second and third screenings in order to categorize thyroid tissues simply and objectively. However, in this study, patients with a DIO1-or DIO2-overexpressing thyroid showed typical clinical features of T 3 -predominant Graves' disease, such as high FT 3 to FT 4 ratio, high TRAb, and a large goiter size, in the third screening. Furthermore, all seven genes showed a significant increase in their expression level in the high TRAb and FT 3 to FT 4 ratio groups and in the large goiter group. Thus, we could conclude that these genes also characterize T 3 -predominant Graves' tissues. However, there are some limitations in this study. First, we have not validated the protein expression of the detected genes. Secondly, almost all patients analyzed received medication at surgery and it was not clear to what extent such medication altered gene expression in the thyroid.
Although the prevalence of T 3 -predominant Graves' disease was reported to be high in younger patients in the previous studies (2, 6), the mean age of patients with a DIO1-or DIO2-overexpressing thyroid was higher than that of those with a DIO1-or DIO2-underexpressing thyroid. Probably, this was caused by some social factors, as a considerable number of young patients with a small goiter prefer to undergo surgery to achieve early remission before marriage or employment. LRNN1 regulates the subcellular localization of specific components of signaling or cell-to-cell recognition pathways (10) . BMP8A plays a role in calcium regulation and bone homeostasis (11) . CDH2 is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium-dependent cell-to-cell adhesion glycoprotein composed of five extracellular cadherin repeats, a transmembrane region, and highly conserved cytoplasmic tail (12) . PDE1A plays a role in signal transduction by regulating intracellular cyclic nucleotide concentrations through hydrolysis of cAMP and/or cGMP (13) . CKMT2 is responsible for the transfer of high-energy phosphate from mitochondria to the cytosolic carrier, creatine (14) . ITGB3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin, and von Willebrand factor (15) . PTPN4 acts at junctions between the membrane and the cytoskeleton (16) .
There is little information on the relationship between these genes and thyroid cell function. In a papillary thyroid carcinoma cell line, TPC-1, ITGB3 expression was found to correlate with RET-mediated invasion in a mouse tumor xenograft model, suggesting that ITGB3 contributes to cell adhesion and migration downstream of RET (17) . It is notable that four of seven genes, LRRN1, CDH2, ITGB3, and PTPN4, are associated with cellular adhesion. Even though their exact functions in thyroid follicular cells are not clear, they might contribute to the morphological changes in the thyroid tissue of T 3 -predominant Graves' disease.
The pathogenesis of T 3 -predominant Graves' disease is not fully understood. High titer of TRAb followed by intense TSH stimulation has been believed to be the cause of T 3 -predominant Graves' disease. In fact, in this study, a significant increase in TRAb was observed in both DIO1 and DIO2 mRNA-overexpressing groups and all seven genes showed increased expression in the TRAb high group. However, this hypothesis does not fully explain high D1 and D2 expression, a high prevalence in young patients and typical morphological changes in T 3 -predominant Graves' disease.
Our data showing increased expression of CDH2 mRNA in the T 3 -predominant Graves' tissues may lead to another explanation. Some similarities between thyroid follicular tumors and T 3 -predominant Graves' disease should be noted. Follicular tumors often express a high level of D1O1 or DIO2 and thyroid autonomous adenomas overexpress not only DIO1 but also CDH2 (18, 19, 20) . In recent years, a novel hypothesis named fetal cell carcinogenesis, in which thyroid tumor cells are derived from the remnants of fetal thyroid cells, has attracted increasing attention (21, 22) . In this hypothesis, three types of fetal thyroid cell are thought to provoke cancer by generating thyroid cancer cells: anaplastic and papillary carcinomas are derived from thyroid stem cells and thyroblasts respectively and follicular tumors are derived from prothyrocytes. An interesting feature that arises from this hypothesis is that not only thyrocytes but also fetal thyroid cells, probably prothyrocytes that are considered to be the origins of follicular thyroid tumors, are likely to remain in the thyroid of the young. Such fetal thyroid cells are not only the origin of follicular tumors but also control the volume of the thyroid gland by proliferating into thyrocytes. If we hypothesize that T 3 -predominant Graves' disease is caused by an increased number of differentiated fetal thyroid cells remaining in the young that can be origins of follicular tumors, we can easily answer the following three questions about T 3 -predominant Graves' disease: why its prevalence is high in younger patients, why it shows a large goiter, and why its tissue overexpresses D1 and D2, as such fetal thyroid cells overexpress D1 and D2 and possess high proliferative ability.
The existence of immature thyroid cells in the thyroid gland has long been discussed without any definitive evidence. This is partly because no effective markers have been known to identify such fetal thyroid cells. If the above hypothesis is true, the seven genes identified in this study might be used not only in understanding the pathological mechanism of T 3 -predominant Graves' disease but also in the detection of fetal thyroid cells.
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